Geopolitical conflict in Iran threatens global medicine supply chains: systemic risks and structural vulnerabilities exposed

Traditional medicine systems in the Middle East and South Asia have historically provided resilience during pharmaceutical shortages, yet are systematically excluded from global health policy frameworks. Iranian Unani medicine, for example, relies on locally sourced herbs and has been used to treat chronic diseases when Western drugs are inaccessible, but its integration into modern supply chains is actively discouraged by pharmaceutical lobbyists. The erasure of these systems reflects a colonial legacy where Western biomedicine is prioritized over indigenous knowledge, despite its proven adaptability in crises.

The current crisis is the latest iteration of a 45-year pattern where U.S. sanctions on Iran have disrupted medical supply chains, dating back to the 1979 hostage crisis and intensifying under Trump’s 'maximum pressure' campaign. Similar disruptions occurred during the Iran-Iraq War (1980–1988), when sanctions forced Iran to develop indigenous pharmaceutical production, only for these capacities to be dismantled in the 1990s under neoliberal structural adjustment programs. Historical parallels include the 1990s Yugoslav Wars, where sanctions led to medicine shortages and the rise of black-market pharmaceutical networks, demonstrating how economic warfare consistently destabilizes public health.

Cross-culturally, medicine access during conflicts often relies on community-based networks rather than state or corporate systems. In Cuba, the 'medical internationalism' model has sent doctors to over 160 countries during crises, while in Kerala, India, local self-help groups maintain 'medicine libraries' where members share surplus drugs. These models contrast sharply with the Western just-in-time supply chain, which prioritizes efficiency over redundancy and equity. The reliance on such systems in the Global South highlights the failure of neoliberal globalization to provide equitable health outcomes.

Pharmaceutical supply chains are highly concentrated, with 80% of active pharmaceutical ingredients (APIs) produced in just a few countries (China, India, and the EU), making them vulnerable to geopolitical shocks. Studies show that sanctions on Iran have reduced its ability to import critical APIs, leading to a 30% increase in counterfeit medicines in the region. The 'just-in-time' production model, while cost-effective, lacks buffers for systemic shocks, as demonstrated by COVID-19 disruptions. Scientific consensus supports diversifying production hubs and stockpiling critical medicines, yet these solutions are rarely implemented due to corporate resistance.

Art and spiritual practices have long been used to cope with and contextualize health crises in the Middle East. Persian miniature art often depicts healers and medicinal herbs, reflecting the cultural reverence for pharmacology, while Sufi poetry (e.g., Rumi) frames illness as a metaphor for spiritual imbalance, encouraging holistic approaches to healing. In Lebanon, during the 2020 Beirut port explosion, mural artists transformed damaged buildings into 'healing walls,' symbolizing community resilience. These artistic responses highlight how culture can reframe health crises as opportunities for collective care rather than mere logistical failures.

Scenario modeling suggests that without systemic changes, future conflicts in key transit regions (e.g., Strait of Hormuz, Red Sea) could disrupt 60% of global medicine shipments within 30 days, triggering cascading shortages in Africa and Southeast Asia. Alternative models, such as 'pharmaceutical sovereignty'—where nations prioritize local production of essential medicines—could reduce vulnerability by 40% but require significant investment in R&D and infrastructure. Climate change exacerbates these risks by increasing the frequency of extreme weather events that disrupt supply chains, necessitating adaptive planning. The most resilient futures will likely emerge from hybrid models combining traditional knowledge, decentralized production, and global cooperation.

Marginalized communities—refugees, women-headed households, and rural populations—are disproportionately affected by medicine shortages, yet their perspectives are excluded from policy discussions. In Iran, Afghan refugees face systemic barriers to healthcare due to lack of documentation, while in Yemen, women are often denied access to medicines due to gendered mobility restrictions. Indigenous groups in the Amazon, who rely on plant-based medicines, are increasingly displaced by resource extraction, further eroding their ability to self-medicate. The framing of this crisis as a 'supply chain issue' ignores the intersectional vulnerabilities that determine who suffers most.